Synthekine Joins Quest To Tame IL-2 In Cancer Therapies. First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.
Related StoriesNovartis... https://t.co/46n9lBkdmi #PharmaScrip
The Breakthrough of the Year @AAAS Bhaumik Prize goes to the 2 scientists who pushed/fought to get GLP-1 drugs to treat obesity (which took decades!)
https://t.co/EFAB5pczbd by @MeaganPhelan, with the whole, fascinating story
pleased to be a member of the selection committee
@adamfeuerstein This is awesome! My son and I are doing Star Wars calendar with Funko mini-figures this year. Favorite has been Chewie tangled in lights
Winners | Losers of Biopharma for 2023
A newsroom-wide list with dozens of entries ... and emojis to match
Check out our review of the year: https://t.co/oJfkr3Mjwn
@ArmstrongDrew@ky_lahucik I never thought I'd see "Painful but Hilarious Clinical Findings" in a headline. At least there are still hundreds of reasons to believe it will be the most effective pain killer ever
Next month, Truvian will present performance of its blood testing solution from a recent multisite #clinicalstudy at the @_AACC Annual Scientific Meeting. Read more about our poster presentation: https://t.co/emvh9trYpw
@matthewherper Loved this - "I enjoyed feeling the weight of the information in my hands. It felt like stepping back onto dry land after a long boat ride." So much nostalgia
Hi everyone - I am looking for my next career opportunity. I have 20+ years of experience, including a journalism career (Bloomberg, bylines in NYT, SF Chron) + a decade in PR, working at an agency (W2O) and in-house at biopharma (J&J, Audentes, Resilience & Kriya). DMs are open!
Today we announced positive results from our Ph3 EXPLORER-CN trial of mavacamten for the treatment of Chinese patients w/ oHCM. Learn more about the data and the impact access will have for patients in need: https://t.co/cdADBL2INV #LIAN $LIAN #data